| abstract |
In the present invention, general formula (1) [wherein (a) represents a single bond or a double bond; W represents CH, CH 2 , CHCH 3 , CCH 3 , C (CH 3 ) 2 group, C (CH 2) 2 group (i.e., with binding to the spiro - carbon atoms have two methylene groups forming the cyclopropane units) or C (CH 2) 3 group (i.e., with binding to the spiro - cyclobutane units (A carbon atom having two methylene groups to be formed) wherein W represents exclusively a CH or CCH 3 group when (a) is a double bond and (a) is a single bond In which case W represents CH 2 , CHCH 3 , C (CH 3 ) 2 , C (CH 2 ) 2 or a C (CH 2 ) 3 group); X is a carbon atom (CH) having a hydrogen atom or A nitrogen atom; Y is a carbon atom having a hydrogen atom Or a fluorine atom], addition salts thereof, and, in some cases, hydrates of pharmaceutically acceptable inorganic or organic acids and addition salts, and their tautomeric forms, pure enantiomers and Enantiomeric mixture (racemic or not). [Chemical 1] |